Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8278443rdf:typepubmed:Citationlld:pubmed
pubmed-article:8278443lifeskim:mentionsumls-concept:C0030193lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0012010lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0021798lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0001962lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0030883lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0016566lld:lifeskim
pubmed-article:8278443lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:8278443pubmed:issue3lld:pubmed
pubmed-article:8278443pubmed:dateCreated1994-2-9lld:pubmed
pubmed-article:8278443pubmed:abstractTextThere are two phases to the behavioral response to injection of formalin. After an initial vigorous response, a period of reduced pain occurs 10 to 15 min after formalin, followed by reemergence of pain-related behaviors. These phases are believed to represent acute chemical stimulation of afferent neurons followed by injury-related inflammatory pain. Pentobarbital (10, 15, or 25 mg/kg), diazepam (0.5, 1.5, or 5.0 mg/kg), or ethanol (0.5, 1.0, or 1.5 g/kg) attenuated the diminution of pain between the two phases, so that pain was continuous throughout 60 min of testing, but had no effect on pain scores during the peaks of either phase. The effects of pentobarbital and diazepam were blocked by picrotoxin (2.5 mg/kg), which itself had no effect. Ro 15-1788 also blocked the effect of diazepam. Picrotoxin did not effectively antagonize the effect of ethanol. A high dose of picrotoxin (5.0 mg/kg) caused seizures in some rats and also eliminated the interphase depression of pain. The results suggest that the biphasic time course of formalin pain is produced by a central antinociceptive mechanism that is inhibited by GABAA receptors.lld:pubmed
pubmed-article:8278443pubmed:languageenglld:pubmed
pubmed-article:8278443pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:citationSubsetIMlld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8278443pubmed:statusMEDLINElld:pubmed
pubmed-article:8278443pubmed:monthNovlld:pubmed
pubmed-article:8278443pubmed:issn0091-3057lld:pubmed
pubmed-article:8278443pubmed:authorpubmed-author:FranklinK BKBlld:pubmed
pubmed-article:8278443pubmed:authorpubmed-author:AbbottF VFVlld:pubmed
pubmed-article:8278443pubmed:issnTypePrintlld:pubmed
pubmed-article:8278443pubmed:volume46lld:pubmed
pubmed-article:8278443pubmed:ownerNLMlld:pubmed
pubmed-article:8278443pubmed:authorsCompleteYlld:pubmed
pubmed-article:8278443pubmed:pagination661-6lld:pubmed
pubmed-article:8278443pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:meshHeadingpubmed-meshheading:8278443-...lld:pubmed
pubmed-article:8278443pubmed:year1993lld:pubmed
pubmed-article:8278443pubmed:articleTitlePentobarbital, diazepam, and ethanol abolish the interphase diminution of pain in the formalin test: evidence for pain modulation by GABAA receptors.lld:pubmed
pubmed-article:8278443pubmed:affiliationDepartment of Psychology, McGill University, Montreal, Canada.lld:pubmed
pubmed-article:8278443pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8278443pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8278443lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8278443lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8278443lld:pubmed